Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Collyar: What's In It for Patients?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Aug
07
Today In Oncology
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer
AMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer
WHO Calls for Action in New Status Report on Cancer
FDA Approves Oncolytic Viral Therapy With Immunotherapy for Advanced Melanoma
Trastuzumab Rezetecan Improves Progression-Free Survival in HER2-Positive Metastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo